Cedrik Britten, the former head of oncology cell therapy research at GlaxoSmithKline Plc, has joined Immatics Biotechnologies GmbH as chief medical officer. The biopharmaceutical company discovers and develops T cell redirecting immunotherapies for cancer. Dr Britten has 10 years experience in clinical and preclinical research in the field of immuno-oncology. He held senior positions at BioNTech SE before joining GSK. Dr Britten qualified as a physician at the Johannes Gutenberg University in Mainz, Germany.
Immatics Biotechnologies GmbH announced the appointment on 4 June 2020.
Copyright 2020 Evernow Publishing Ltd